Publications by authors named "Meltzer-Brody S"

Objective: Hypothalamic-pituitary-adrenal (HPA) axis dysregulation has been implicated in the pathogenesis of perinatal mood disorders. Further, HPA axis response is known to be blunted during breastfeeding. We hypothesized that 1) postpartum depression/anxiety symptoms would be associated with HPA axis dysregulation, indexed by loss of expected adrenocorticotropic hormone (ACTH)-cortisol coupling, and 2) this association would vary by method of infant feeding.

View Article and Find Full Text PDF
Article Synopsis
  • The pandemic intensified awareness of depression's impact throughout life, prompting healthcare systems and advocates to prioritize prevention and treatment.
  • Efforts continue to tackle the challenge of treating adult patients with difficult-to-treat depression who don’t respond to standard medications, while the psychiatric workforce faces limitations.
  • The University of Arizona hosted the Southwest Forum on Difficult to Treat Depression in July 2024, bringing together experts to discuss innovative treatment methods, effective care algorithms, and improving access to depression care.
View Article and Find Full Text PDF

Depressive disorders present an enormous global public health burden. A notable treatment gap exists between the prevalence of depression and our ability to provide rapid-acting, effective treatment that achieves remission. Brexanolone and zuranolone, the first US Food and Drug Administration-approved drugs for postpartum depression, signify a critical advancement in addressing the unmet needs of a vulnerable patient population.

View Article and Find Full Text PDF

Postpartum depression (PPD) is a mood disorder affecting one in seven women after childbirth that is often under-screened and under-detected. If not diagnosed and treated, PPD is associated with long-term developmental challenges in the child and maternal morbidity. Wearable technologies, such as smartwatches and fitness trackers (e.

View Article and Find Full Text PDF

Despite the evidence for the effectiveness of psychosocial interventions for perinatal depression, their uptake is low in Low- and Middle-Income Countries. Reasons for this include the lack of contextually adapted interventions and mental health specialists to deliver them. This study aimed to test the acceptability and feasibility of a psychosocial intervention for perinatal depression, the Thinking Healthy Programme-Peer Delivered, adapted for use in rural Malawi.

View Article and Find Full Text PDF

Introduction: Major depression (MD) is more common amongst women than men, and MD episodes have been associated with fluctuations in reproductive hormones amongst women. To investigate biological underpinnings of heterogeneity in MD, the associations between depression, stratified by sex and including perinatal depression (PND), and blood biomarkers, using UK Biobank (UKB) data, were evaluated, and extended to include the association of depression with biomarker polygenic scores (PGS), generated as proxy for each biomarker.

Method: Using female ( = 39,761) and male ( = 38,821) UKB participants, lifetime MD and PND were tested for association with 28 blood biomarkers.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to compare the effectiveness of zuranolone, a new oral treatment for postpartum depression (PPD), with selective serotonin reuptake inhibitors (SSRIs) and other combination therapies in adults in the U.S.
  • Using randomized controlled trials and advanced statistical methods, the research highlighted that patients treated with zuranolone had a significantly greater reduction in depression symptoms (measured by the EPDS scale) compared to those on SSRIs, especially noticeable by Day 15 and Day 45.
  • However, limitations included a lack of population overlap between the studies, which affected the analysis and introduced some uncertainty regarding the results.
View Article and Find Full Text PDF

Postpartum depression (PPD) affects nearly 20% of postpartum women in Sub-Saharan Africa (SSA), where HIV prevalence is high. Depression is associated with worse HIV outcomes in non-pregnant adults and mental health disorders may worsen HIV outcomes for postpartum women and their infants. PPD is effectively treated with psychosocial or pharmacologic interventions; however, few studies have evaluated the acceptability of treatment modalities in SSA.

View Article and Find Full Text PDF
Article Synopsis
  • This analysis examined the effects of zuranolone, a treatment for major depressive disorder and postpartum depression, on health-related quality of life, using data from four clinical trials.
  • Results indicated that patients taking zuranolone showed significant improvements in various health domains compared to those on placebo, both at 15 days and 42 days after treatment.
  • Zuranolone responders demonstrated consistent benefits across all health aspects measured, with sustained improvements even after the treatment ended.
View Article and Find Full Text PDF
Article Synopsis
  • Perinatal depression affects around 20% of women in North America during pregnancy or shortly after, leading to significant economic costs, estimated at over $45 billion USD in the US and $20.6 billion CAD in Canada.
  • Limited access to psychological treatments for these women is a major issue, but solutions like task-sharing with non-specialists and telemedicine may enhance care delivery, though their cost-effectiveness compared to traditional methods is not yet known.
  • This study will evaluate the economic aspects of using non-specialist providers and telemedicine in treating perinatal depression as part of the SUMMIT trial, which will analyze cost-effectiveness and healthcare resource use across multiple North American sites.
View Article and Find Full Text PDF

Background: Perinatal depression affects >400,000 mother-child dyads in the United States every year and is associated with numerous adverse maternal and child developmental outcomes. Previous research implicates the dysregulation of oxytocin and the hypothalamic-pituitary-adrenal (HPA) axis functioning in mothers and children as potential mechanisms mediating or moderating the transmission of risk associated with maternal depression.

Objective: The Mood, Mother and Child study will examine the psychobiological sources of risk and resilience within mother-child dyads affected by maternal depression.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on postpartum depression (PPD), a hereditary form of major depressive disorder, using genome-wide association studies (GWAS) to explore its genetic basis across various populations.
  • It analyzed data from 18,770 PPD cases and 58,461 controls, finding no single-nucleotide polymorphisms (SNPs) that met genome-wide significance, though it highlighted significant genetic correlations with other mental health conditions.
  • The findings suggest that PPD is polygenic and heritable, potentially involving unique genetic factors despite its close relationship with major depressive disorder and implicate specific brain neurons associated with its treatment.
View Article and Find Full Text PDF

Background: Option B + offers lifelong ART to pregnant or breastfeeding mothers, but postpartum loss to HIV care, partially driven by perinatal depression (PND), threatens the impact of this policy. This study aims to understand women's and providers' preferences for developing a feasible intervention to address PND and support engagement in HIV care among women living with PND and HIV.

Methods: We conducted a total of 6 focus group discussions (FGDs) involving 4 clinics in Lilongwe District from December 2018 through February 2019.

View Article and Find Full Text PDF
Article Synopsis
  • This article explores new neurosteroid treatments for postpartum depression (PPD), highlighting their development, clinical trial results, and future prospects in the field.
  • It specifically covers brexanolone, the first FDA-approved fast-acting antidepressant for PPD, its clinical trials, and the challenges associated with its intravenous administration.
  • The article also discusses exciting advancements like zuranolone and ganaxolone, emphasizing the role of GABA signaling and inflammation in depressive disorders to potentially improve treatments for PPD and major depressive disorders.
View Article and Find Full Text PDF

Introduction: Sex steroid hormone fluctuations may underlie both reproductive disorders and sex differences in lifetime depression prevalence. Previous studies report high comorbidity among reproductive disorders and between reproductive disorders and depression. This study sought to assess the multivariate genetic architecture of reproductive disorders and their loading onto a common genetic factor and investigated whether this latent factor shares a common genetic architecture with female depression, including perinatal depression (PND).

View Article and Find Full Text PDF
Article Synopsis
  • Postpartum depression (PPD) is a common issue affecting new mothers, and this study explored the effectiveness and safety of zuranolone as a treatment option over a 14-day period.
  • In a phase 3 trial with 196 participants, those taking zuranolone showed significant improvements in depression scores compared to those on a placebo, with benefits noted as early as day 3.
  • The treatment was well tolerated, with some side effects like somnolence and dizziness, but no serious risks such as loss of consciousness or increased suicidal thoughts were reported.
View Article and Find Full Text PDF

More than 70% of children with one or more mental health diagnoses in North Carolina are not receiving treatment. For many families, emergency departments have become the frontline providers of pediatric behavioral health care. There is a great need for more behavioral health services, a bigger workforce, and environments where children and adolescents can thrive.

View Article and Find Full Text PDF

Brexanolone, a formulation of the neurosteroid allopregnanolone (ALLO), is approved for treating postpartum depression (PPD) and is being investigated for therapeutic efficacy across numerous neuropsychiatric disorders. Given ALLO's beneficial effects on mood in women with PPD compared to healthy control women, we sought to characterize and compare the cellular response to ALLO in women with ( = 9) or without ( = 10, i.e.

View Article and Find Full Text PDF

Objectives: To examine: (1) the psychometric properties of two therapist competence measures-multiple choice questionnaire (MCQ) and standardized role-plays; (2) whether therapist competence differed between non-specialist (NSPs) and specialist (SPs) providers; and (3) the relations between therapist competence and patient outcomes among perinatal patients receiving brief psychotherapy.

Methods: This study is embedded within the SUMMIT Trial-a large, ongoing psychotherapy trial for perinatal women with depressive and anxiety symptoms. We assessed the: (1) psychometric properties of therapist competence measures using Cronbach's alpha and inter-class correlation; (2) differences in therapist competence scores between n = 23 NSPs and n = 22 SPs using a two-sample t-test; and (3) relations between therapist competence measures and perinatal patient outcomes through a linear regression model.

View Article and Find Full Text PDF

Perinatal depression (PND) is common and an important barrier to engagement in HIV care for women living with HIV (WLHIV). Accordingly, we adapted and enhanced The Friendship Bench, an evidence-based counseling intervention, for perinatal WLHIV. In a pilot randomized trial (NCT04143009), we evaluated the feasibility, acceptability, fidelity, and preliminary efficacy of the Enhanced Friendship Bench (EFB) intervention to improve PND and engagement in HIV care outcomes.

View Article and Find Full Text PDF

Objective: To identify psychological, medical, and socioenvironmental risk factors for maternal postpartum depression (PPD) and severe psychological distress (SPD) at intensive care nursery discharge among mothers of very preterm infants.

Study Design: We studied 562 self-identified mothers of 641 infants born <30 weeks who were enrolled in the Neonatal Neurobehavior and Outcomes in Very Preterm Infants Study (NOVI) conducted in nine university-affiliated intensive care nurseries. Enrollment interviews collected socioenvironmental data, depression, and anxiety diagnoses prior to and during the study pregnancy.

View Article and Find Full Text PDF

Perinatal perceived stress can contribute to worse health outcomes for the parent-child dyad. Given the emerging relationship between the microbiota-gut-brain axis and stress, this study sought to elucidate connections between bowel symptoms and the gut microbiome in relation to perceived stress at three time points in the perinatal period: two during pregnancy and one postpartum. Ninety-five pregnant individuals participated in a prospective cohort study from April 2017 to November 2019.

View Article and Find Full Text PDF